Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib vs Cyclophosphamide in Early Diffuse Cutaneous Systemic Sclerosis
NCT06044844Phase 2Unknown
- Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Start
- Nov 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tofacitinib in systemic sclerosis (SSc) (2 arms), sponsored by Bangabandhu Sheikh Mujib Medical University. Primary endpoint: Skin thickness at 24 weeks. Status: unknown.
02
Drugs
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT06044844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06044844.